Actively Recruiting

Phase Not Applicable
Age: 50Years - 100Years
All Genders
NCT06862557

Pulsed Electromagnetic Field Treatment With Dementia Patients

Led by Herrick Medical LLC · Updated on 2025-05-18

48

Participants Needed

1

Research Sites

78 weeks

Total Duration

On this page

Sponsors

H

Herrick Medical LLC

Lead Sponsor

U

University of Miami

Collaborating Sponsor

AI-Summary

What this Trial Is About

An open label pilot study in mild to moderate AD/ADRD patients to assess the effects of treatment with ECHS AD/ADRD pulsed electromagnetic treatment device on disease progression. Enrolled patients will receive active devices. They will treat themselves at home three times a day for 15 minutes over 120 days. Primary end point is the The Alzheimer's Disease Assessment Scale-Cognitive Subscale. Participants will be followed-up for 9 months post-treatment.

CONDITIONS

Official Title

Pulsed Electromagnetic Field Treatment With Dementia Patients

Who Can Participate

Age: 50Years - 100Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 50 years or older
  • Diagnosed with mild to moderate Alzheimer's disease or related dementias including Lewy body dementia and vascular dementia, with a global Clinical Dementia Rating of 0.5 or 1
  • At least eighth grade level of education
  • If female, post-menopausal
  • Mini-Mental State Examination (MMSE) score between 16 and 26 inclusive
  • Able to provide consent or have a surrogate able to consent if participant lacks capacity
  • Willing and able to follow the study protocol
  • If taking cholinesterase inhibitors or memantine, medication must be stable for at least 60 days prior to screening and continued throughout the study
  • Physically cleared by a clinician for study participation
Not Eligible

You will not qualify if you...

  • Lack of capacity to consent without available surrogate
  • No study partner available for interview
  • History of epileptic seizures or epilepsy
  • Diagnosis of Frontotemporal Dementia
  • Taking medication that lowers seizure threshold (excluding blood thinners)
  • Currently taking anti-amyloid monoclonal antibodies (past treatment allowed if stopped at least 3 months before baseline)
  • Presence of depression, bipolar disorder, psychotic disorder, or other neurological or psychiatric conditions interfering with study
  • Severe agitation interfering with study procedures
  • Alcoholism or substance use disorder within past 5 years or severe sleep deprivation
  • Major surgery requiring general anesthesia and hospitalization for more than 1 week within past 4 weeks
  • Head anatomy preventing proper fit of the treatment device
  • Participation in another clinical trial within past 30 days
  • Metal implants in the head (except mouth implants) such as cochlear implants or brain stimulators
  • Conditions increasing risks associated with blood draws

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University of Miami

Boca Raton, Florida, United States, 334233

Actively Recruiting

Loading map...

Research Team

M

Magdalena Tolea, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here